To evaluate longer-term (5-7 years) outcomes of the twelve (12) subjects treated with AGN1 Femoral LOEP in the clinical study "A Prospective Pilot Evaluation of Percutaneous Osteo-supplementation in the Proximal Femur of Osteoporotic Patients". Performance will be evaluated via medical history evaluation, X-ray, DXA, CT and mobility testing. The study will look at the extent to which the benefits demonstrated in the initial, baseline study were sustained over time. In this manner, it may be possible to determine the rate of change in BMD following the treatment; thereby allowing prediction of the total benefit period. In addition, this longer period of observation allows for further evaluation of the safety profile of the material in osteoporosis patients.
This observational single arm study will be broken into two parts: 1. A retrospective component which will evaluate the original FRAX score along with any events or medications received after the end of the original study. 2. A prospective component which will evaluate longer term outcomes following the use of the AGN1 synthetic bone graft material in a local osteoenhancement procedure through evaluation of mobility and imaging. In the original study, subjects completed a twenty-four (24) month follow-up visit after receiving a unilateral hip injection with the device. The contralateral hip acted as the control. The purpose of the study was to determine the safety of the injection as well as the initial improvement in femoral bone density in a twenty-four (24) month period. In this follow-up study the subjects, after signing the informed consent form, will complete a short medical history (focused on their osteoporosis management) and a mobility test. Subjects will also undergo a DXA, X-ray and CT scans of both hips.
Study Type
OBSERVATIONAL
Enrollment
12
Bone Mineral Density
Bone mineral density (BMD) assessed by DXA scans (T-score ) of the treated hip compared to nontreated hip (femoral neck).
Time frame: through study completion, an average of 30 days
Bone Mineral Density
Bone mineral density (BMD) assessed by DXA scans (absolute value measurement) of the treated hip compared to nontreated hip (femoral neck).
Time frame: through study completion, an average of 30 days
Bone Mineral Density
Percent change compared to baseline for the treated femoral neck measurement of BMD.
Time frame: through study completion, an average of 30 days
Bone Mineral Density
Percent change compared to baseline for the untreated femoral neck measurement of BMD.
Time frame: through study completion, an average of 30 days
Bone Mineral Density
Bilateral hip CT scan analysis of the trabecular bone density.
Time frame: through study completion, an average of 30 days
Bone Mineral Density
Bilateral hip CT scan analysis of the trabecular bone volume.
Time frame: through study completion, an average of 30 days
Bone Mineral Density
Bilateral hip CT scan analysis of the cortical bone density.
Time frame: through study completion, an average of 30 days
Bone Mineral Density
Bilateral hip CT scan analysis of the cortical bone volume.
Time frame: through study completion, an average of 30 days
Bone Mineral Density
Bilateral hip CT scan analysis of any qualitative observations compared to baseline CT scans.
Time frame: through study completion, an average of 30 days
Subject Interview
All osteoporosis related events (as defined by the Investigator) from the twenty-four (24) month follow-up visit to current point-in-time including fragility fractures, changes in mobility and medication reactions.
Time frame: through study completion, an average of 30 days
Subject Interview
All osteoporosis medication use including vitamins and supplements from the twenty-four (24) month follow-up visit to current point-in-time.
Time frame: through study completion, an average of 30 days
Subject Interview
Any physical activity/exercise program from the twenty-four (24) month follow-up visit to current point-in-time.
Time frame: through study completion, an average of 30 days
FRAX Index Risk Assessment
Comparative calculation of a FRAX index for hip fracture risk based on BMD data from the treatment and contralateral hip using pre-procedure data compared to current point-in-time.
Time frame: through study completion, an average of 30 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.